Telomir Pharmaceuticals, Inc. has announced a significant financial move that could bolster its clinical development efforts. On October 5, 2026, the company entered into a securities purchase agreement that will see it raise approximately $5.6 million through a private placement of shares. This funding is crucial as it will primarily support the clinical development of Telomir-Zn, a treatment aimed at advanced or metastatic triple-negative breast cancer.
The private placement involves the sale of 4,843,300 shares of the company's common stock at a price of $1.16 per share, which reflects a 5% discount to the stock's 10-day volume-weighted average price prior to the closing of the deal. Notably, John Paul DeJoria, a significant existing shareholder, participated by investing an additional $1 million in this offering.
Telomir Pharmaceuticals operates in the pharmaceutical preparations sector, focusing on innovative treatments for serious health conditions. The recent filing, accession number 0001493152-26-045860, outlines the details of the private placement and its intended use of proceeds, which also includes general corporate purposes and working capital.
The agreement includes customary representations, warranties, and covenants for a transaction of this nature. Alongside the purchase agreement, the company has also entered into a registration rights agreement, committing to file a registration statement with the U.S. Securities and Exchange Commission within 30 days to facilitate the resale of the shares.
Alexander Capital, L.P. is acting as the placement agent for this private placement, and the company will pay a cash fee of approximately $455,000 based on the gross proceeds. Additionally, Alexander Capital will receive warrants to purchase 387,464 shares of common stock, further aligning their interests with the success of Telomir Pharmaceuticals.
This funding marks a pivotal moment for Telomir Pharmaceuticals as it continues to advance its clinical programs, particularly for Telomir-Zn, which is currently in Phase 1/2 trials for treating aggressive forms of breast cancer. The company’s ability to attract significant investment from both existing and new shareholders reflects a strong belief in its future potential and the innovative nature of its treatment pipeline.
As Telomir Pharmaceuticals moves forward with its clinical development plans, the pharmaceutical industry will be closely watching how this funding impacts its research and development efforts, especially in the competitive landscape of cancer treatments.
The filing does not specify what happens next, but the company is expected to proceed with its clinical trials and utilize the raised funds effectively to enhance its market position.